Donald A. Denkhaus Sells 20,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) Director Donald A. Denkhaus sold 20,000 shares of the stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $15.34, for a total value of $306,800.00. Following the sale, the director now owns 297,666 shares of the company’s stock, valued at $4,566,196.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $13.41 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $17.22. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 26.29 and a beta of 1.31. The firm’s 50-day simple moving average is $12.20 and its 200 day simple moving average is $9.11.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CPRX. FMR LLC lifted its position in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 822 shares in the last quarter. Point72 Hong Kong Ltd lifted its position in Catalyst Pharmaceuticals by 84.3% in the 4th quarter. Point72 Hong Kong Ltd now owns 5,932 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,713 shares in the last quarter. Covestor Ltd lifted its position in Catalyst Pharmaceuticals by 768.0% in the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,316 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $62,000. Finally, Quantamental Technologies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $72,000. Institutional investors own 74.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CPRX shares. Roth Capital cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $10.00 to $15.50 in a research report on Wednesday, August 24th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, August 11th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 8th. Finally, HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, August 11th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $14.81.

About Catalyst Pharmaceuticals

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.